JNJ: רווח למניה בשנים עשר החודשים האחרונים Johnson & Johnson Co.

Business restructuring has allowed Johnson & Johnson (JNJ) to focus on medicine, as evidenced by the trailing 12-month earnings per share: the parameter value is 6.63. This trend is based on the global implementation of low-cost proprietary developments. Stability is ensured by conservative management and a long-term track record of dividend growth, which is clearly visualized on this chart.
פילוחי מדדים פיננסיים ומדדי שוק עבור Johnson and Johnson (JNJ)

This indicator reflects the aggregate net income of Johnson & Johnson (JNJ) distributed per common share over the last twelve months, allowing for an assessment of the real efficiency of capital generation for shareholders. The growth in the TTM earnings per share confirms the strong pricing power of Johnson & Johnson (JNJ) and the inelastic demand for its unique patent portfolio, which ensures revenue stability even amidst inflationary pressures.